List of Excipients in Branded Drug VECURONIUM BROMIDE

Generic Drugs Containing VECURONIUM BROMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	vecuronium bromide	0143-9234	CITRIC ACID ACETATE
Hikma Pharmaceuticals USA Inc	vecuronium bromide	0143-9234	MANNITOL
Hikma Pharmaceuticals USA Inc	vecuronium bromide	0143-9234	PHOSPHORIC ACID
Hikma Pharmaceuticals USA Inc	vecuronium bromide	0143-9234	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in VECURONIUM BROMIDE?

# Of NDCs	Excipient
13	ANHYDROUS CITRIC ACID
2	CITRIC ACID ACETATE
15	MANNITOL
15	PHOSPHORIC ACID

Vecuronium Bromide Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Vecuronium bromide is an established generic neuromuscular-blocking agent used as an adjunct to general anesthesia and mechanical ventilation. Its core molecule has no meaningful remaining composition-of-matter exclusivity in the United States. Commercial value therefore depends on manufacturing reliability, sterile-product quality, formulation stability, presentation, hospital procurement economics, and supply-chain performance rather than conventional patent protection.

The strongest product opportunities are a stable lyophilized injectable, differentiated vial configurations, ready-to-use presentations, and supply programs targeting hospitals, ambulatory surgery centers, emergency departments, and international markets. Excipient selection must preserve chemical stability, rapid reconstitution, sterility, low particulate burden, and compatibility with common infusion systems.

What is the FDA regulatory status of vecuronium bromide?

Vecuronium bromide is an FDA-approved injectable neuromuscular blocker. The originator product, Norcuron, was approved under NDA 018478. Current generic products are generally marketed as sterile vecuronium bromide for injection under the abbreviated new drug application pathway.

Regulatory attribute	Vecuronium bromide
Active ingredient	Vecuronium bromide
Therapeutic class	Nondepolarizing neuromuscular blocker
Route	Intravenous injection
Principal use	Adjunct to general anesthesia and mechanical ventilation
FDA pathway for generics	ANDA under section 505(j)
Originator	Norcuron
Originator approval	1980s
Dosage forms	Lyophilized powder for injection
Common vial strengths	10 mg and 20 mg
Biosimilar pathway	Not applicable
Current market structure	Generic hospital injectable market

The FDA label requires administration by trained clinicians with adequate anesthesia, airway management, respiratory support, and reversal capabilities. Vecuronium produces skeletal-muscle paralysis but does not provide unconsciousness or analgesia. The labeling also identifies risks associated with residual neuromuscular blockade, respiratory compromise, anaphylaxis, medication errors, and dosing in patients with hepatic, biliary, or renal impairment. [1]

Vecuronium is commonly reconstituted with sterile water for injection, 0.9% sodium chloride, 5% dextrose, or other labeled compatible diluents. Product-specific labeling controls the permitted diluents, storage period after reconstitution, temperature conditions, and administration instructions.

What excipients are used in vecuronium bromide injection?

The conventional excipient system is a lyophilized sterile powder containing a bulking agent, a buffer, and pH-control components. Common labeled excipients include mannitol, citric acid, and disodium phosphate, although the exact amounts and grades vary by manufacturer. [1,2]

Excipient function	Common material	Commercial purpose
Bulking and cake formation	Mannitol	Provides an acceptable lyophilized cake and supports vial handling
Buffering	Disodium phosphate	Controls pH during manufacture and reconstitution
Acidification and pH adjustment	Citric acid	Supports the target formulation pH
Diluent at use	Sterile water, sodium chloride, dextrose solutions	Reconstitutes the powder before intravenous administration
Container protection	Type I borosilicate glass, elastomeric closure	Preserves sterility and chemical quality

Mannitol is commercially attractive because it is widely available, compatible with lyophilization, and generally accepted in parenteral products. Its use must be balanced against cake structure, residual moisture, reconstitution time, and potential crystallization behavior during freezing and drying.

The citrate-phosphate system requires close control. Buffer concentration affects pH, reconstitution performance, chemical degradation, and compatibility with infusion solutions. A formulation that is too weak may experience pH drift. A formulation that is too strong may increase ionic load or alter stability during lyophilization.

The excipient composition is not merely a qualitative generic-equivalence issue. For an ANDA, the sponsor must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. Changes in excipient quantity, buffer species, vial fill, or reconstitution conditions can affect product quality and may require additional development and regulatory work.

What excipient strategy best supports a commercial vecuronium product?

The highest-probability strategy is a conservative lyophilized formulation that closely follows the established excipient architecture. The commercial objective should be lower manufacturing risk, not unnecessary formulation novelty.

Strategy 1: Optimize the conventional lyophilized formulation

A conventional mannitol-buffer system offers the clearest regulatory path. Development priorities include:

• Consistent cake appearance and mechanical strength
• Short reconstitution time
• Low residual moisture
• Limited vial-to-vial potency variation
• Acceptable pH after reconstitution
• Low visible and subvisible particulate levels
• Stability under refrigerated and controlled-room-temperature conditions
• Compatibility with the labeled diluents
• Low adsorption to glass and elastomeric surfaces

The formulation should be tested through a forced-degradation program covering heat, light, oxygen, moisture, agitation, and freeze-thaw exposure. Stability-indicating analytical methods should distinguish vecuronium degradation products from excipient-related impurities.

Strategy 2: Develop a higher-concentration vial

A 20 mg vial can reduce the number of units required for larger procedures and may lower preparation time. Its value is strongest in operating rooms with frequent use and standardized anesthesia protocols.

The principal risks are incomplete dissolution, greater concentration-dependent degradation, increased dosing-error exposure, and a mismatch between vial strength and typical procedural doses. A 20 mg presentation should not be treated as automatically superior to a 10 mg vial. Hospitals may prefer the 10 mg format because it reduces waste for short cases.

Strategy 3: Offer a low-waste 10 mg presentation

The 10 mg vial is commercially relevant because vecuronium dosing is weight-based and procedural requirements vary. A small vial can reduce unused drug, particularly in ambulatory surgery and lower-volume facilities.

A supplier can differentiate through:

• Low minimum order quantities
• Unit-dose packaging
• Barcoded cartons
• Tall-man labeling
• Clear reconstitution instructions
• Compatible syringe and vial-transfer systems
• Reliable short-lead-time supply

In a mature generic market, these procurement attributes can matter more than minor excipient changes.

Strategy 4: Pursue a ready-to-use liquid only with a clear stability advantage

A ready-to-use vecuronium solution could reduce preparation steps and medication errors. It would also create a more complex regulatory and manufacturing program.

A liquid product must address:

• Chemical stability in solution
• Sterility over the proposed shelf life
• Container-closure integrity
• Oxygen and light sensitivity
• Adsorption to syringe or tubing materials
• Particulate control
• Preservative strategy
• Administration-device compatibility
• Cold-chain requirements

A preservative-free single-dose liquid would be more suitable for intravenous use than a multidose format, but it could impose higher fill-finish costs and tighter stability constraints. A manufacturer should not add a preservative solely to extend shelf life without demonstrating compatibility, safety, and a clear clinical or operational benefit.

Strategy 5: Develop a premixed syringe or cartridge

A prefilled syringe could target emergency departments, operating rooms, and procedural areas where rapid administration and dose standardization are valuable. The main barriers are device compatibility, extractables and leachables, silicone-oil control, needle integrity, and the need to validate the drug-device combination.

This strategy is more defensible commercially than a novel excipient system if the product reduces preparation time and medication errors. It may fit a 505(b)(2) development strategy if the product materially changes the dosage form or delivery system, but the regulatory pathway would depend on the extent of the difference from the approved injectable product.

What patents protect vecuronium bromide?

No commercially significant unexpired United States composition-of-matter patent is expected to protect vecuronium bromide. The originator product was approved decades ago, and the foundational exclusivity period has expired.

IP category	Current commercial relevance
Vecuronium molecule	Foundational protection expired
Original injectable formulation	Historical protection expired
Basic lyophilization concept	Generally difficult to enforce broadly
Specific excipient ratios	Potentially protectable if novel and non-obvious
Ready-to-use liquid	Potential formulation and device claims possible
Prefilled syringe	Potential device and combination-product claims
Manufacturing process	Possible process protection
Container-closure system	Possible narrow patent protection
Method of use	Limited value where standard anesthesia use is established
Biosimilar exclusivity	Not applicable

A new entrant could obtain patents on a narrowly defined formulation, a stable liquid composition, a specific lyophilization cycle, a low-particulate container system, or a prefilled delivery device. Those patents would protect the new presentation, not the underlying vecuronium molecule.

Patentability would depend on demonstrating a technical effect such as:

• Unexpected long-term stability
• Improved reconstitution time
• Reduced degradation
• Lower particulate formation
• Better compatibility with a specific container
• Reduced adsorption
• Improved room-temperature storage
• Reduced preparation errors

Routine substitution of one pharmaceutically acceptable buffer for another would face a higher obviousness risk. A patent estate based solely on conventional excipients and ordinary concentration changes would likely be narrow.

When does vecuronium bromide lose exclusivity?

Vecuronium bromide has already lost its core FDA exclusivity. The market is open to ANDA applicants, subject to pharmaceutical-equivalence, bioequivalence, manufacturing, labeling, and current good manufacturing practice requirements.

What is the Orange Book status of vecuronium bromide?

The Orange Book is relevant to the reference-listed drug and any listed patents or exclusivity. For an old generic injectable such as vecuronium bromide, commercial entry generally does not depend on overcoming a live composition patent. The practical review issues are product selection, reference-product designation, bioequivalence, sterility assurance, and manufacturing capacity.

A sponsor should confirm the current Orange Book entry and FDA product database before filing because marketing status, discontinued-product coding, reference-product designation, and listed patents can change. The central commercial conclusion remains that vecuronium is a mature generic product with no known strategic barrier comparable to a protected branded injectable. [3]

Are Paragraph IV challenges relevant?

Paragraph IV litigation is not a principal market risk for ordinary vecuronium bromide injection. A Paragraph IV certification would matter only if a relevant patent were listed for the reference product. Because the core molecule and conventional injectable formulation are long-established, the more likely pathway is a Paragraph III or “no relevant patent” position, depending on the current Orange Book record and the applicant’s product.

A reformulated liquid, prefilled syringe, or novel delivery system could create new patent disputes. Those disputes would concern the new formulation or device claims, not basic generic access to lyophilized vecuronium.

What formulations are protected by vecuronium bromide patents?

The commercially important formulation categories are conventional lyophilized powder, ready-to-use liquid, and device-integrated presentations.

Formulation	Technical opportunity	Patent strength
Mannitol-buffered lyophilized powder	Lower cost and established regulatory profile	Low to moderate if claims are narrow
Improved lyophilized cake	Faster reconstitution and lower residual moisture	Moderate if supported by unexpected data
Preservative-free liquid	Eliminates reconstitution	Moderate to high if stability is difficult to achieve
Prefilled syringe	Reduces preparation and dosing steps	Moderate, with device overlap risk
Dual-chamber system	Separates unstable components until use	Potentially strong but costly
Novel infusion container	Supports closed-system preparation	Narrow, device-dependent

A patent strategy should cover composition, process, container, and use where justified. The strongest claims would connect a defined excipient range to measurable performance. Broad claims covering “vecuronium plus a pharmaceutically acceptable excipient” would face validity and freedom-to-operate concerns.

How strong is the vecuronium bromide patent estate?

The legacy patent estate is weak for blocking generic entry. A new entrant’s patent position could be moderate if it develops a technically differentiated presentation supported by comparative stability and usability data.

Strengths

• Long clinical history
• Established intravenous route
• Familiar hospital use
• Well-characterized active ingredient
• Multiple potential formulation and device improvements
• No biosimilar development requirement

Weaknesses

• Mature molecule with extensive prior art
• Limited room for broad composition claims
• Conventional excipients are well known
• Hospital buyers often prioritize price and supply continuity
• Novel presentations may face limited willingness to pay
• Formulation patents may be vulnerable to design-around

The best protection is likely a layered estate covering a specific liquid composition, an improved freeze-drying process, a container-closure combination, and a prefilled delivery device. Patent value would depend on whether hospitals pay for the resulting workflow or stability benefit.

Which companies are challenging vecuronium bromide?

Vecuronium bromide is primarily a generic competition market. Competition comes from generic injectable manufacturers and from clinically substitutable neuromuscular blockers rather than from branded challengers pursuing a high-value patent battle.

Relevant competing products include:

• Rocuronium bromide
• Atracurium besylate
• Cisatracurium besylate
• Pancuronium bromide
• Succinylcholine chloride

Rocuronium is the closest commercial substitute in many operating-room protocols. It has a faster onset than vecuronium and can be reversed with sugammadex. Vecuronium remains relevant where hospitals prioritize established protocols, lower acquisition cost, and familiarity with the product. [4,5]

Product	Competitive distinction	Commercial effect
Vecuronium	Established, low-cost nondepolarizing blocker	Price and supply driven
Rocuronium	Faster onset; reversal with sugammadex	Strong procedural substitute
Cisatracurium	Organ-independent Hofmann elimination profile	Attractive in selected ICU patients
Atracurium	Established alternative with histamine-related considerations	Protocol-dependent substitute
Succinylcholine	Rapid onset and short duration	Emergency airway alternative
Pancuronium	Longer duration	Narrower contemporary use

What generic entry risks exist for vecuronium bromide?

Generic entry risk is already realized. The strategic risks now relate to price erosion, procurement consolidation, manufacturing interruptions, and substitution by competing neuromuscular blockers.

A new manufacturer faces five commercial barriers:

1. Sterile injectable manufacturing capacity
2. Reliable supply of validated vials, stoppers, and active ingredient
3. Hospital formulary access
4. Demonstration of consistent supply at competitive pricing
5. Ability to withstand low-volume, low-margin procurement contracts

Hospitals may award business through group purchasing organizations and contract tenders. A product with no meaningful formulation differentiation may need to compete on acquisition price and shortage performance. A differentiated presentation can command better economics only when it reduces labor, waste, medication errors, or inventory complexity.

What manufacturing and IP barriers affect vecuronium bromide?

The main barriers are operational rather than molecular.

Sterile manufacturing

The product requires validated aseptic processing, lyophilization, container-closure integrity testing, particulate testing, sterility testing, bacterial endotoxin control, and ongoing environmental monitoring. Lyophilization adds cycle-development complexity and increases dependence on equipment availability.

Active pharmaceutical ingredient

Vecuronium bromide API supply must meet identity, assay, impurity, residual-solvent, elemental-impurity, and microbiological requirements. Dual sourcing can reduce disruption risk but may require comparability work and process validation.

Packaging

Type I glass vials and elastomeric closures can affect adsorption, extractables, reconstitution, and stability. A commercial product should evaluate multiple stopper formulations and sterilization methods before finalizing the container-closure system.

Intellectual property

Freedom-to-operate analysis should cover:

• Specific buffer and bulking-agent ranges
• Liquid formulations
• Prefilled syringes
• Closed-system transfer devices
• Lyophilization cycles
• Vial and stopper combinations
• Stability-enhancing excipients
• International formulation patents

The underlying molecule is unlikely to be the principal IP constraint.

What licensing deals and commercial partnerships exist for vecuronium bromide?

Vecuronium bromide has no widely reported current licensing transaction comparable to the partnerships associated with novel branded medicines. Commercial arrangements are more likely to involve:

• Contract manufacturing
• API supply
• Regional distribution
• Hospital group-purchasing contracts
• Private-label injectable supply
• Co-development of prefilled syringes
• Government or emergency-stockpile procurement

A licensee would have greater leverage if it brings sterile fill-finish capacity, a validated lyophilization process, or a differentiated delivery device. A simple license to an old vecuronium formulation is less likely to generate substantial royalty economics.

What is the revenue exposure for vecuronium bromide?

Product-specific revenue is generally not disclosed by generic manufacturers. The addressable market is tied to procedure volume, intensive-care use, hospital purchasing, and the relative use of rocuronium and other neuromuscular blockers.

Revenue potential is strongest in:

• Large hospital systems
• Ambulatory surgery centers
• Emergency airway programs
• Intensive-care units
• Government tenders
• Markets with limited local sterile injectable capacity
• Countries where rocuronium or sugammadex access is constrained by cost

The product is unlikely to support premium pricing solely through a different excipient profile. Commercial upside requires a measurable operational benefit, such as reduced preparation time, longer shelf life outside refrigeration, lower vial waste, or improved supply continuity.

How does vecuronium compare with rocuronium commercially?

Rocuronium has a stronger clinical differentiation profile because of faster onset and compatibility with sugammadex reversal. Vecuronium competes more effectively on cost, established use, and procurement familiarity.

Factor	Vecuronium	Rocuronium
Core market position	Mature generic	Mature generic with stronger procedural differentiation
Onset	Slower than rocuronium	Faster
Reversal	Neostigmine and supportive management; sugammadex also binds vecuronium	Neostigmine and sugammadex
Excipient opportunity	Lyophilized-to-liquid and device improvements	Similar formulation and device opportunities
Price pressure	High	High, but clinical value can support demand
Patent opportunity	New formulation and device claims	New formulation and device claims
Main commercial threat	Substitution by rocuronium	Price competition and substitution by alternatives

A vecuronium supplier should position the product as a reliable, low-cost hospital injectable unless it can prove a clear workflow benefit. The formulation strategy should not assume that excipient novelty alone will change clinical demand.

Key Takeaways

• Vecuronium bromide has no meaningful remaining core-molecule exclusivity in the United States.
• The conventional excipient system uses a lyophilized powder with mannitol and citrate-phosphate buffering components.
• The lowest-risk commercial strategy is an optimized generic lyophilized vial.
• The most credible differentiated opportunities are ready-to-use liquids, prefilled syringes, low-waste vial sizes, and improved room-temperature stability.
• Patent value will come from narrowly defined formulation, process, container, or device claims.
• Paragraph IV litigation is not the primary risk for conventional vecuronium injection.
• Biosimilar competition is irrelevant because vecuronium is a small-molecule drug.
• Rocuronium is the principal clinical and commercial substitute.
• Sterile manufacturing reliability and hospital contracting are more important than legacy molecule patents.
• A premium product requires evidence of reduced preparation burden, waste, errors, or supply interruptions.

FAQs

Can mannitol be replaced in a vecuronium bromide lyophilized formulation?

Yes, but the replacement would require formulation, lyophilization, stability, reconstitution, and pharmaceutical-equivalence evaluation. Mannitol is used because it supports cake formation and is widely accepted in sterile products.

Is a liquid vecuronium bromide injection commercially attractive?

It can be attractive if it provides adequate shelf life, low particulate levels, and operational advantages over reconstituted powder. The development burden is materially higher because vecuronium stability in solution must be demonstrated across the proposed storage period.

Does vecuronium bromide require a biosimilar application?

No. Vecuronium bromide is a small-molecule drug. A generic injectable would generally use the ANDA pathway, while a substantially reformulated or device-integrated product could require a different FDA strategy.

Can a new vecuronium formulation receive patent protection?

Yes. A formulation, manufacturing process, container system, or delivery device may be patentable if it is novel, non-obvious, and supported by reproducible technical benefits. The claims would not protect the old molecule itself.

What is the best commercial vial strength for vecuronium bromide?

Both 10 mg and 20 mg formats have commercial logic. The 10 mg vial can reduce waste in short procedures, while the 20 mg vial can improve efficiency for larger cases. The optimal mix depends on hospital procedure volume and purchasing contracts.

References

1. U.S. Food and Drug Administration. (2023). Vecuronium bromide for injection prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2023). Norcuron prescribing information. FDA-approved labeling.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2015). Bridion (sugammadex) prescribing information. FDA-approved labeling.

5. U.S. Food and Drug Administration. (2023). Zemuron (rocuronium bromide) prescribing information. FDA-approved labeling.